Incyte Corporation
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- William J. Meury
- Full Time Employees
- 2,844
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1801 Augustine Cut-Off Wilmington DE United States of America 19803
- IPO Date
- Nov 4, 1993
- CIK
- 0000879169
- Website
- incyte.com
- Similar Companies
- Business
- Incyte Corporation (INCY) is a Wilmington, Delaware-based biopharmaceutical company founded in 2002 that discovers, develops, and commercializes proprietary medicines for oncology, inflammation, autoimmunity, and dermatology; it operates globally in North America, Europe, and Asia with over 2,500 employees focused on unmet medical needs. The company markets a diversified portfolio of approved products including Jakafi (ruxolitinib) for myelofibrosis, polycythemia vera, and graft-versus-host disease; Opzelura (ruxolitinib) cream for atopic dermatitis and vitiligo; Pemazyre (pemigatinib) for cholangiocarcinoma and myeloid/lymphoid neoplasms; Monjuvi (tafasitamab-cxix) for relapsed or refractory diffuse large B-cell lymphoma; Tabrecta (capmatinib) for non-small cell lung cancer; Iclusig (ponatinib) for leukemia; and Olumiant (baricitinib) for rheumatoid arthritis and alopecia areata; it also advances a robust pipeline of clinical candidates discovered in-house targeting immunology, hematology-oncology, and inflammatory skin conditions. Recent developments include the 2024 acquisition of Escient Pharmaceuticals for $750 million to add first-in-class oral MRGPRX2 antagonists EP262 for hidradenitis suppurativa, prurigo nodularis, and other pruritic skin diseases and EP547 for pruritus in kidney and liver diseases; FDA approval of Niktimvo (axatilimab-csfr) with partner Syndax Pharmaceuticals in August 2024 for chronic graft-versus-host disease; relocation of over 300 Pennsylvania jobs to expanded downtown Wilmington headquarters by 2026 supporting more than 500 positions; and a 2025 roadmap featuring four potential product launches such as ruxolitinib XR and povorcitinib expansions, four pivotal trial readouts, seven proof-of-concept disclosures, and at least three Phase 3 initiations toward over 10 high-impact launches by 2030.
Company News
Incyte Corporation: Why Jakafi Is No Longer The Real Story Here
84,502 Shares in Incyte Corporation $INCY Bought by Beacon Pointe Advisors LLC
Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in Brazil
Incyte (INCY) Up 0.8% Since Last Earnings Report: Can It Continue?
Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Analog Devices, Crown Castle, ebay, EPR Properties, Etsy, Merck & Co., Shopify, TJX Companies, and More
Global Vitiligo Foundation Applauds Incyte's “Moments of Clarity” Campaign for Elevating Patient Voices and Advancing Vitiligo Awareness
Incyte Sales Growth Drives Share Price Gains
Cetera Investment Advisers Has $2.40 Million Position in Incyte Corporation $INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REGN or INCY: Which Is the Better Value Stock Right Now?
New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
Here's Why Incyte (INCY) is a Strong Momentum Stock
Here's Why Incyte (INCY) is a Strong Growth Stock
Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis
INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised
Incyte Corporation (INCY) Q2 2026 Earnings Call Transcript
Here's Why Incyte (INCY) is a Strong Value Stock
Compared to Estimates, Incyte (INCY) Q2 Earnings: A Look at Key Metrics
Incyte Q2 Earnings Call Highlights
Incyte: From Buy To Hold After A 93% Rally (Rating Downgrade)